Wall Street analysts expect Eli Lilly and Company (NYSE:LLY) to report earnings of $1.04 per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Eli Lilly and’s earnings, with the lowest EPS estimate coming in at $1.00 and the highest estimate coming in at $1.06. Eli Lilly and reported earnings of $0.86 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 20.9%. The firm is expected to issue its next quarterly earnings report before the market opens on Tuesday, July 25th.
According to Zacks, analysts expect that Eli Lilly and will report full-year earnings of $4.12 per share for the current year, with EPS estimates ranging from $4.09 to $4.15. For the next fiscal year, analysts expect that the firm will report earnings of $4.42 per share, with EPS estimates ranging from $4.29 to $4.66. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow Eli Lilly and.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 10.13% and a return on equity of 26.64%. The firm had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. During the same quarter in the previous year, the firm posted $0.86 earnings per share. The company’s revenue was up 7.8% on a year-over-year basis.
A number of research firms recently weighed in on LLY. Cowen and Company increased their price objective on shares of Eli Lilly and from $85.00 to $95.00 and gave the stock an “outperform” rating in a research report on Monday, April 17th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $88.00 price objective on shares of Eli Lilly and in a research report on Sunday, May 21st. TheStreet cut shares of Eli Lilly and from a “b+” rating to a “c” rating in a research report on Wednesday, May 31st. Morgan Stanley cut shares of Eli Lilly and from an “overweight” rating to an “equal weight” rating and set a $82.00 price objective for the company. in a research report on Monday, April 17th. Finally, Citigroup Inc. reaffirmed a “buy” rating and set a $100.00 price objective on shares of Eli Lilly and in a research report on Thursday, April 6th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $87.75.
Eli Lilly and (NYSE LLY) traded down 3.01% during mid-day trading on Tuesday, hitting $82.19. 13,319,876 shares of the stock traded hands. The stock has a market cap of $86.82 billion, a P/E ratio of 39.74 and a beta of 0.35. The stock has a 50-day moving average price of $82.56 and a 200-day moving average price of $81.26. Eli Lilly and has a 12 month low of $64.18 and a 12 month high of $86.72.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th will be issued a $0.52 dividend. The ex-dividend date is Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.53%. Eli Lilly and’s payout ratio is 100.48%.
In other news, insider Melissa S. Barnes sold 1,900 shares of the firm’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $80.78, for a total value of $153,482.00. Following the sale, the insider now directly owns 14,041 shares in the company, valued at approximately $1,134,231.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 215,000 shares of the firm’s stock in a transaction on Tuesday, June 20th. The shares were sold at an average price of $83.05, for a total transaction of $17,855,750.00. Following the completion of the sale, the insider now owns 124,475,804 shares in the company, valued at $10,337,715,522.20. The disclosure for this sale can be found here. Insiders sold a total of 474,733 shares of company stock worth $39,634,487 over the last 90 days. Company insiders own 0.20% of the company’s stock.
Several large investors have recently made changes to their positions in LLY. Pinnacle Financial Partners Inc. raised its stake in shares of Eli Lilly and by 24.3% in the fourth quarter. Pinnacle Financial Partners Inc. now owns 31,574 shares of the company’s stock worth $2,323,000 after buying an additional 6,170 shares during the last quarter. RB Capital Management LLC bought a new stake in shares of Eli Lilly and during the fourth quarter valued at approximately $341,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new stake in shares of Eli Lilly and during the fourth quarter valued at approximately $46,505,000. Independent Advisor Alliance bought a new stake in shares of Eli Lilly and during the fourth quarter valued at approximately $1,547,000. Finally, Archford Capital Strategies LLC raised its stake in shares of Eli Lilly and by 53.9% in the fourth quarter. Archford Capital Strategies LLC now owns 12,730 shares of the company’s stock valued at $935,000 after buying an additional 4,456 shares in the last quarter. Institutional investors and hedge funds own 75.56% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://stocknewstimes.com/2017/08/04/zacks-brokerages-anticipate-eli-lilly-and-company-nyselly-to-announce-1-04-earnings-per-share-updated.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Get a free copy of the Zacks research report on Eli Lilly and (LLY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
